Mark Agulnik

Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Margaret von Mehren, John M. Kane, Mark Agulnik et al. · Journal of the National Comprehensive Cancer Network · 2022 · 1.2K citations · Full text

Medicine, Oncology, Surgery +17

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

William D. Tap, Robin L. Jones, Brian A. Van Tine et al. · The Lancet · 2016 · 588 citations

Medicine, Oncology, Pharmacology +9

Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer

Ezra E.W. Cohen, Theodore Karrison, Masha Kocherginsky et al. · Journal of Clinical Oncology · 2014 · 569 citations · Full text

Medicine, Oncology, Radiation Oncology +15

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

Wan‐Teck Lim, Boon Cher Goh, Edwin P. Hui et al. · Journal of Clinical Oncology · 2018 · 466 citations · Full text

Medicine, Oncology, Pharmacology +17

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

Mrinal M. Gounder, Patrick Schöffski, Robin L. Jones et al. · The Lancet Oncology · 2020 · 406 citations

Medicine, Cancer Biology, Oncology +12